Tuesday, November 29, 2016 1:46:54 PM
Question on Momenta's biosimilar Humira not efficacy, but legality, says Maxim.
Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.
Read more at: http://thefly.com/landingPageNews.php?id=2469383
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM